Market Dynamics

Rapid technological advancements in cell culture industry, high investment by major players for product development and focus on introduction of new easy to use and versatile products are major factors expected to drive the growth of global 3D perfusion bioreactor system market. Cell culture refers to removal of cells from an animal or plant and their subsequent growth in a favorable artificial environment. Manufacturers are investing high for drug development. Their approach towards product development in order to deliver advanced product to biopharmaceutical companies for growing stem cells and for tissue engineering applications. Manufactures approach towards enhancing the product portfolio and increase the revenue share is expected to impact the growth of 3D perfusion bioreactor system market.

In 2018, Sartorius Stedim Biotech, a global supplier to biopharmaceutical companies launched Ambr 250 High Throughput (ht) perfusion. The system is automated parallel bioreactor and is specifically designed for rapid cell culture perfusion process development to optimize production of therapeutic antibodies. This helped the company to enhance the business and increase the revenue share. In addition, players are focused on enhancing the business presence through agreements and establishment of new facilities overseas this is expected to augment the growth of 3D perfusion bioreactor system market.

In 2018, TA Instruments a global manufacturer of biotechnology equipments and devices partnered with Integrated Modern Scientific Supplies – Gulf Bio Analytical Group in order to distribute company’s product in Saudi Arabia. This agreement helped the company to enhance the business presence in Middle East region and strengthen its business.

In 2017, 3D Biotek a global biomedical engineering company established new GMP facility in US. The established facility helped the company to enhance the R&D and manufacturing capabilities further increasing the company revenue.

Increasing government expenditure on biotechnology sector and high focus on strengthening the manufacturing ability by upgrading the present infrastructure are factors expected to boost the growth of 3D perfusion bioreactor system market. In addition, favorable business polices by the government of developing countries is expected to support the revenue transaction of the target 3D perfusion bioreactor system market. India allows 100% FDI under the automatic route (a non-resident or Indian company will not require any approval from the government) for greenfield pharmaceuticals and manufacturing medical devices. Easy availability of raw material and low cost labor is attracting major manufacturers to shift their production facilities to emerging countries. Factors such as high cost associated to R&D and devices are major factors expected to hamper the growth of global 3D perfusion bioreactor system market.

In addition, stringent government regulations related to product approval is expected to challenge the growth of 3D perfusion bioreactor system market. However, increasing investment by major players for R&D activities, focus on development of cost-effective products and focus on tracking the untapped market in emerging economies are factors expected to create new opportunities for players operating in 3D perfusion bioreactor system market. In addition, increasing merger and acquisition activities by major players in order to enhance the product portfolio and customer base is responsible for the growth of target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global 3D perfusion bioreactor system market due to high government spending on cell culture industry. In addition, presence of large number of players operating in the country and introduction of new products is expected to boost the regional market growth.

The market in Asia Pacific is expected to witness faster growth in the target market due to flourishing biotechnology sector and increasing investment for R&D activities. Supportive financial aid from the government and emergence of small & mid-size enterprises is expected to support the growth of 3D perfusion bioreactor system market. According to IBEF the biotechnology industry comprises >2,700 biotech start-ups and >2,500 biotech companies in the country.

Competitive Landscape

The global 3D perfusion bioreactor system market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

3D Perfusion Bioreactor System Market Segment Analysis, 2019

The global 3D perfusion bioreactor system market is segmented into type and application. The type segment is bifurcated into components and device. Among the type the device segment is expected to account for major revenue share in the global 3D perfusion bioreactor system market due to rapid technological advancements by manufacturers. The application segment is divided into biopharmaceutical companies, biotechnology, and others. Among application, the biopharmaceutical companies segment is expected to account for major revenue share in the target market. The players profiled in the report are TA Instruments, Sigma-Aldrich, 3D Biotek, CELLEC BIOTEK AG, Biogenuix, Sartorius AG, and SYNTHECON.

Market Segmentation

Market By Type

Components
Device

Market By Application

Biopharmaceutical Companies
Biotechnology
Others

Market By Geography

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa